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Background:  Streptococcus  pneumoniae  is  a major  cause  of morbidity  and  mortality  among  adults  50
years  of  age  and  older  in  the  United  States.  Pneumococcal  conjugate  vaccines  are  efﬁcacious  against
pneumococcal  disease  in  children  and  may  also  offer  advantages  in  adults.
Methods:  We  performed  a randomized,  modiﬁed  double-blind  trial that  compared  a single  dose  of  13-
valent  pneumococcal  conjugate  vaccine  (PCV13)  with  23-valent  pneumococcal  polysaccharide  vaccine
(PPSV23)  in  831  pneumococcal  vaccine  naive  adults  60–64  years  of age.  An additional  group  of 403  adults
50–59 years  of age received  open-label  PCV13.  Anti-pneumococcal  opsonophagocytic  activity  (OPA) titers
were  measured  at baseline,  and  at 1 month  and  1 year  after  vaccination.
Results:  In the  randomized  trial, the  month  1 post-vaccination  OPA  geometric  mean  titers  in the PCV13
group  were  statistically  signiﬁcantly  higher  than  in  the PPSV23  group  for  8 of the  12  serotypes  common
to  both  vaccines  and  for serotype  6A,  a serotype  unique  to PCV13,  and  were  comparable  for  the  other
4  common  serotypes.  The  immune  response  to PCV13  was  generally  greater  in  adults  50–59 years  of
age  compared  to adults  60–64  years  of  age. OPA  titers  declined  from  1  month  to 1  year  after  PCV13
administration  but  remained  higher  than  pre-vaccination  baseline  titers.
Conclusions:  PCV13  induces  a greater  functional  immune  response  than  PPSV23  for the majority  of
serotypes  covered  by  PCV13,  suggesting  that  PCV13  could  offer  immunological  advantages  over  PPSV23
for  prevention  of vaccine-type  pneumococcal  infection.© 201
Abbreviations: AE, adverse event; CI, conﬁdence interval; CRM197, cross-reactive ma
neumococcal disease; LLOQ, lower limit of quantitation; LOD, limit of detection; OPA, 
CV7,  7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjug
istribution curve; SAE, serious adverse event.
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. Introduction
Streptococcus pneumoniae is a major cause of morbidity and
ortality among older adults in the United States. Currently in
he United States the 23-valent pneumococcal polysaccharide vac-
ine (PPSV23) is recommended for adults 65 years of age and
lder, as well as for high-risk younger adults, for prevention of
nvasive pneumococcal disease (IPD) [1,2]. However, PPSV23 has
ome limitations. While the vaccine is believed to be moderately
ffective in prevention of IPD in immunocompetent older adults,
ffectiveness wanes over time, and a protective effect against non-
acteremic pneumococcal pneumonia has not been consistently
emonstrated [3]. In contrast, pneumococcal conjugate vaccines
PCVs) are highly effective against vaccine-type IPD in children
nd have also been shown to reduce the risk of all-cause pneu-
onia. In addition, a 7-valent PCV (PCV7) has been shown to
e effective against vaccine-type IPD in a randomized controlled
rial of HIV-infected adults. These data suggest potential advan-
ages for the use of PCVs compared to PPSV23 in older adults
4–8].
We  conducted a randomized trial to compare the immunogenic-
ty, tolerability, and safety of a 13–valent PCV (PCV13) with PPSV23
n pneumococcal vaccine-naive adults 60–64 years of age. In addi-
ion, a cohort of subjects 50–59 years of age received a single dose
f open-label PCV13 to compare immune responses between the
ounger and older age groups.
 
Consented (n=
Included in evaluable immunogenicity population (n=411)            
 Excluded from  evaluable immunogenicity population (n=7)*  
 Not in all-available im munogenicity population (n=1) 
 Not eligible  for the study (n=2) 
 No postvaccination blood draw  (n=3) 
 Postvaccination blood draw out of window (n=2) 
 Received prohibited vaccine (n=1) 
 Other protocol violation (n=2) 
Withdrawn (n=13) 
 Investigator request (n=1) 
 Subject request (n=4) 
 Protocol violation (n=7) 
 Death (n=1) 
 
PCV13 (n=418) 
 Received allocated vaccine (n=417)  
 Did not receive allocated vaccine (n=1; discontinued 
prior to vaccination) 
Withdrawn (n=18) 
 Investigator request (n=1) 
 Subject request (n=7) 
 Protocol violation (n=3) 
 Lost to follow-up (n=6) 
 Adverse event (n=1) 
PPSV23 (n
 Received allocated vaccine (n 
 Did not receive allocated vacc
prior to vaccination ) 
Included in evaluable immunogen
 Excluded from  evaluable immun
 Not in all-available im munog
 No postvaccination blood dra 
 Postvaccination blood draw o
 Received prohibited vaccine 
 
Allocation 
Anal ysis 
Follow-Up Up to 1  year postvaccination 
Enrollment  
Adults 60-64 Years of Age    
*Subjects could have been excluded for more than one reason. 
Fig. 1. Study design and di1 (2013) 3577– 3584
2. Methods
2.1. Study design and populations
This was a randomized, modiﬁed double-blind, multicenter
phase 3 trial of adults 60–64 years of age conducted in the USA in
25 medical centers. This study was  undertaken in accordance with
the Declaration of Helsinki and Good Clinical Practice [9,10]. The
study population included persons with pre-existing underlying
chronic conditions (e.g. cardiovascular, pulmonary, renal, liver dis-
eases including alcoholic liver disease and alcoholism, and diabetes
mellitus). Disease had to be stable, deﬁned as not requiring signif-
icant change in therapy or hospitalization for worsening disease
12 weeks prior to vaccination. Participants were excluded if they
had serious chronic disorders including metastatic malignancy,
severe chronic obstructive pulmonary disease requiring supple-
mental oxygen, end-stage renal disease with or without dialysis,
clinically unstable cardiac disease, impaired immune function, or
had previously received a PPSV23 dose or any prior PCV.
After obtaining informed consent, eligible subjects were ran-
domized with equal probability to receive PCV13 or PPSV23 at the
enrollment visit. In the modiﬁed double-blind design, the vaccines
were dispensed and administered by unblinded study staff mem-
bers not involved in subsequent participant assessments. All other
study staff members and participants were blinded to the vaccine
administered. Participants 50–59 years of age received a single dose
1303); Excluded (n=64; screen failures) 
=417) 
=414) 
ine (n=3; discontinued 
icity population (n=407)   
ogenicity population (n=10)* 
enicity population (n=3) 
w (n=6) 
ut of window (n=4) 
(n=1) 
Withdrawn (n=31) 
 Subject request (n=9) 
 Failed  to return (n=12)  
 Lost to follow-up (n=6) 
 Protocol violation (n=3) 
 Other (n=1) 
PCV13 (n=406) 
 Received allocated vaccine (n=404)  
 Receive allocated vaccine (n=1; discontinued  at a later  
time) 
 Did not receive allocated vaccine (n=2; discontinued 
prior to vaccination) 
Included in evaluable immunogenicity population (n=388)  
 Excluded from  evaluable immunogenicity population (n=18)* 
 Not in all-available im munogenicity population (n=3)  
 Not eligible  for the study (n=2) 
 Prevaccination blood draw out of window (n=1) 
 No postvaccination blood draw  (n=11)  
 Postvaccination blood draw out of window (n=5) 
 Received prohibited vaccine (n=5) 
Adults 50-59 Years of Age    
sposition of subjects.
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f open-label PCV13 at the enrollment visit with no comparator;
PSV23 is not generally recommended in this age group (Fig. 1).
Non-study medications were permitted. Licensed vaccines,
xcept pneumococcal vaccines, could be given according to local
r national recommendations, and could be concomitantly admin-
stered. Inﬂuenza vaccine was permitted, if given at least 14 days
efore or after study vaccination.
Clinic visits occurred at enrollment, 1 month (29–43 days) and
 year (351–379 days) after vaccination with a telephone visit for
 safety assessment at 6 months after vaccination. Blood samples
ere obtained before vaccination and at each clinic visit.
.2. Vaccines and administration
PCV13 (Prevnar 13/Prevenar 13®, Wyeth Vaccines; Lot Num-
er 7-5095-001A) contains polysaccharides of pneumococcal
erotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and
3F individually conjugated to a nontoxic mutant form of diph-
heria toxin cross-reactive material 197 (CRM197). Each 0.5 mL
ose contains 2.2 g of each serotype, except type 6B, which is
ncluded at 4.4 g. Each dose is formulated in 5.0 mM succinate
nd 0.85% sodium chloride at pH 5.8 with 0.125 mg  aluminum as
luminum phosphate and 0.02% polysorbate 80. The vaccine is sup-
lied in single-dose syringes without preservatives and stored at
–8 ◦C.
PPSV23 (Pneumovax 23®, Merck & Company, Inc; Lot Number
743F) consists of a puriﬁed capsular polysaccharide from 12 of the
erotypes included in PCV13 (all except 6A), as well as 11 additional
erotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F). The
accine is formulated to contain 25 g of each of the 23 puriﬁed
olysaccharide serotypes per 0.5 mL  dose of vaccine and contains
henol as a preservative and stored at 2–8 ◦C.
Vaccines were administered by intramuscular injection in the
eltoid using 25 G 1 in. needles.
.3. Study objectives
The primary objectives for the subjects 60–64 years of age
ere to demonstrate that PCV13 was at least as immunogenic
s PPSV23 for the 12 serotypes common to the 2 vaccines, as
easured by opsonophagocytic activity (OPA) titers 1 month after
accination, and to show that the proportion of subjects with
 4-fold increase in OPA titer to serotype 6A (contained only in
CV13) was signiﬁcantly greater in the PCV13 group compared to
he PPSV23 group. A secondary objective was to show statistically
igniﬁcantly higher responses in PCV13 recipients for at least some
f the 12 serotypes in common.
The primary objective for the evaluation of subjects 50–59 years
f age was to demonstrate that PCV13 was at least as immunogenic
n this age group as in subjects 60–64 years of age.
.4. Analysis populations
The evaluable immunogenicity population was the primary
opulation for immunogenicity analyses and consisted of eligible
ubjects who had at least 1 valid and determinate assay result,
eceived the assigned vaccine and no prohibited vaccines, and had
o other major protocol violation. The safety population included
ll subjects vaccinated.
.5. Immunogenicity assessmentsImmunogenicity was assessed by measuring speciﬁc functional
ntibacterial OPA titers using 13 serotype-speciﬁc validated OPA
ssays. Although a speciﬁc level of OPA antibody has not been
hown to correlate with protection against pneumococcal disease1 (2013) 3577– 3584 3579
in adults, OPA antibody responses are generally accepted as a cor-
relate of vaccine-induced protection [11,12]. Titers were deﬁned
as the interpolated reciprocal serum dilution that resulted in
complement-mediated killing of 50% of the assay bacteria. The
lowest titer that can be determined in the assay (limit of detec-
tion [LOD]), regardless of serotype, is 1:8. However, to quantify
functional antibodies with appropriate precision and accuracy,
the lower limit of quantitation (LLOQ) was determined for each
serotype-speciﬁc OPA assay during assay validation. Titers below
the LLOQ were set to a value of 1:4 (half of the LOD).
OPA titers were measured in all blood samples obtained at base-
line, 1 month after vaccination, and in a randomly selected subset
(100 subjects/study group) of blood samples obtained 1 year after
vaccination.
2.6. Safety assessments
Participants recorded local reactions (redness, swelling, pain
and limitation of arm movement of the injected arm), and systemic
events (chills, fatigue, headache, vomiting, decreased appetite,
rash, new generalized muscle pain, aggravated generalized muscle
pain, new generalized joint pain, and aggravated generalized joint
pain), and oral temperature in an electronic diary on the evening
of vaccination and for the next 13 days. Adverse events (AEs) were
collected from enrollment through the month 1 postvaccination
visit, serious adverse events (SAEs) from enrollment through the
month 6 follow-up phone contact, and deaths through the end of
the study.
2.7. Statistical analysis
2.7.1. Sample size estimation
A sample size of approximately 370 subjects per study group in
subjects 60–64 years of age was determined to provide at least 90%
overall power to declare noninferiority of PCV13 versus PPSV23 for
the 12 common pneumococcal antigens using a 2-fold noninferi-
ority criterion for the OPA geometric mean titer (GMT) ratio (i.e.,
lower limit of the 2-sided 95% conﬁdence interval [CI] for the ratio
GMT  PCV13/GMT PPSV23 is greater than 0.5), and assuming a 2-
sided type I error rate of 0.05 and a 5% dropout rate. Data from a
previous trial was  used for computations [13]. This sample size was
sufﬁcient to detect a difference of at least 15% in the proportion of
subjects achieving a 4-fold rise on the 6A serotype with at least 90%
power using a 2-sided type I error rate of 0.05.
A sample size of 370 subjects 50–59 years of age was determined
to provide at least 90% overall power to declare noninferiority
of the response relative to subjects 60–64 years of age for all 13
pneumococcal antigens using a 2-fold noninferiority criterion and
assuming a 5% dropout rate.
2.7.2. Immunogenicity analyses
For the comparison of OPA GMTs elicited by PCV13 rela-
tive to PPSV23, the 2-sided 95% CI on the geometric mean ratio
(GMR) (GMT PCV13/GMT PPSV23) for each of the 12 common
serotypes was  calculated (back-transformed 95% CI for mean dif-
ference on the logarithmic scale computed using the Student
t distribution). Noninferiority of PCV13 relative to PPSV23 was
declared if the lower limit of the 2-sided 95% CI for the GMR
was greater than 0.5 (2-fold criterion). This value was selected
based on matching immunogenicity to efﬁcacy results from several
infant PCV7 or 9-valent PCV efﬁcacy trials [14]. A secondary anal-
ysis assessed statistically signiﬁcantly greater responses elicited
for at least some serotypes. Statistical signiﬁcance was declared
if the lower limit of the 95% CI for the GMR  was >1.0 (>2.0 for
serotype 6A).
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Table 1
Baseline characteristics.
Characteristic 60–64 Year
age group
50–59 Year
Age group
PCV13 N = 417 PPSV23 N = 414 PCV13 N = 403
Female, % 53.5 60.9 61.8
Race, %
White 96.4 94.2 95.0
Black 1.0 2.2 3.5
Asian 0.7 1.4 1.0
Other 1.0 1.4 0.2
American Indian or
Alaska Native
1.0 0.5 0.2
Native Hawaiian or
Other Paciﬁc Islander
0 0.2 0
Hispanic or Latino, % 2.2 3.1 2.0
T
C
o
(
y580 L.A. Jackson et al. / Va
For evaluation of the response to serotype 6A (only in PCV13),
he proportions of subjects achieving a 4-fold rise in OPA titer 1
onth after vaccination were compared between the 2 groups.
uperiority of response for the PCV13 group was declared if the
ower limit of the 2-sided 95% CI computed using Chan and Zhang
ethodology for the difference in proportions (PCV13–PPSV23)
as greater than zero (0) [15].
Analyses comparing responses to PCV13 serotypes in subjects
0–59 years of age relative to subjects 60–64 years of age were
erformed in the same manner as those comparing responses to
CV13 relative to PPSV23.
All analyses were performed using the SAS software package.
o imputations were done for missing data.
.7.3. Safety analyses
Differences in the frequency of local reactions and systemic
vents between PCV13 and PPSV23 were determined and corre-
ponding 95% CIs and p-values generated based on Chan and Zhang
15].
. Results
.1. Baseline characteristics and disposition of subjects
A total of 831 subjects 60–64 years of age received PCV13
N = 417; mean age 61.8 years) or PPSV23 (N = 414; mean age
1.7 years) and 403 subjects 50–59 years of age (mean age
4.4 years) received open-label PCV13 and included in the safety
opulation (Table 1, Fig. 1). In the older group, distribution of
ge, race, and ethnicity were similar in the PCV13 and PPSV23
roups. The large majority of the population was  white, and in
he evaluable population, gender distribution was signiﬁcantly dif-
erent between the PPSV23 group (female: 61.2%, male: 38.8%)
nd the PCV13 group (female: 53.5%, male: 46.5%) (p = 0.027). In
he older and younger age group 20.1% and 17.1% respectively,
ho received PCV13 had 1 or more chronic underlying diseases
ncluding cardiovascular disease, liver disease (including alcoholic
able 2
omparison of pneumococcal OPA GMTs 1 month after vaccination with PCV13 and PPSV
f  age.
Serotype 60–64 Year age group Vaccine comparison
(PCV13 vs PPV23)
PCV13
na = 359–404
PPSV23
na = 367–402
GMTb GMTb Ratioc (95% 
1 146 104 1.4 (1.10
3  93 85 1.1 (0.90
4  2062 1295 1.6 (1.19
5  199 162 1.2 (0.93
6B  1984 788 2.5 (1.82
7F  1120 405 2.8 (1.98
9V  1164 407 2.9 (2.00
14  612 692 0.9 (0.64
18C  1726 925 1.9 (1.39
19A  682 352 1.9 (1.56
19F  517 539 1.0 (0.72
23F  375 72 5.2 (3.67
6A  2593 213 12.1 (8.63
a n = Number of subjects with a determinate OPA titer to the given serotype.
b GMTs were calculated using all evaluable subjects with available data for the speciﬁe
c Ratio of GMTs PCV13 to PPSV23 is calculated by back transforming the mean differen
d CIs for the ratio are back transformations of a conﬁdence interval based on the S
PCV13–PPSV23).
e Ratio of GMTs, 50–59 years to 60–64 years, is calculated by back transforming the me
f CIs for the ratio are back transformations of a conﬁdence interval based on the Stude
ears–60–64 years).Mean age, years (SD) 61.8 (1.4) 61.7 (1.4) 54.4 (2.9)
liver disease and alcoholism), pulmonary disease, renal or uri-
nary tract disease, or diabetes mellitus. 48.7% of older adults and
37.9% of younger adults had a history of smoking (Supplemental
Table S1).
3.2. Immune responses
3.2.1. PCV13 compared to PPSV23 at 1 month after vaccination
The evaluable immunogenicity population of subjects 60–64
years of age consisted of 818 subjects (411 received PCV13 and
407 received PPSV23).
OPA GMTs at baseline were similar in the 2 vaccine groups.
PCV13 OPA GMTs were noninferior to PPSV23 for all 12 common
serotypes and statistically signiﬁcantly greater in PCV13 recipients
for 8 of the 12 common serotypes (1, 4, 6B, 7F, 9V, 18C, 19A, 23F).
For serotype 6A, contained only in PCV13, the OPA GMT  was sub-
stantially greater in PCV13 recipients than in PPSV23 recipients
(Table 2). In addition, the proportion of subjects achieving a 4-fold
increase in OPA titer for serotype 6A was statistically signiﬁcantly
23 in subjects 60–64 years of age and 1 month after PCV13 in subjects 50–59 years
50–59 Year age group Group comparison
(50–59 yr/60–64 yr)
PCV13 na = 350–384
CId) GMTb Ratioe (95% CIf)
, 1.78) 200 1.4 (1.08, 1.73)
, 1.32) 91 1.0 (0.81, 1.19)
, 2.13) 2833 1.4 (1.07, 1.77)
, 1.62) 269 1.4 (1.01, 1.80)
, 3.48) 3212 1.6 (1.24, 2.12)
, 3.87) 1520 1.4 (1.03, 1.79)
, 4.08) 1726 1.5 (1.11, 1.98)
, 1.21) 957 1.6 (1.16, 2.12)
, 2.51) 1939 1.1 (0.86, 1.47)
, 2.41) 956 1.4 (1.16, 1.69)
, 1.28) 599 1.2 (0.87, 1.54)
, 7.33) 494 1.3 (0.94, 1.84)
, 17.08) 4328 1.7 (1.30, 2.15)
d blood draw.
ce between vaccine groups on the logarithmic scale.
tudent t distribution for the mean difference of the logarithms of the measures
an difference between vaccine cohorts on the logarithmic scale.
nt t distribution for the mean difference of the logarithms of the measures (50–59
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Fig. 2. Reverse cumulative distribution curves for OPA titers measured before vaccination and 1 month after PCV13 or PPSV23 administration in subjects 60–64 years of age and 50–59 years of age. One (1) serotype (as noted) is
displayed per panel. Solid lines depict the prevaccination titers and dotted lines depict the postvaccination titers. (–) PCV13, 60–64 yr; (–) PPSV23, 60–64 yr; (–) PCV13, 50–59 yr. Abbreviations: OPA, opsonophagocytic activity;
PCV13,  13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
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Table 3
Local reactions and systemic events reported up to day 14 after vaccination.
60–64 Year age group p-Valuea 50–59 Year age group
PCV13% PPSV23% PCV13%
Local reactions
Rednessb Any 20.2 14.2 0.123 15.8
Mild 15.9 11.2 0.193 15.2
Moderate 8.6 4.9 0.169 5.0
Severe 1.7 0 0.095 0.7
Swellingb Any 19.3 13.1 0.103 21.7
Mild  15.5 10.1 0.120 20.6
Moderate 8.2 4.4 0.150 4.3
Severe 0.6 1.1 0.689 0
Painc Any 80.1 73.4 0.052 88.8
Mild  78.6 68.6 0.005 85.9
Moderate 23.3 30.0 0.125 39.5
Severe 1.7 8.6 0.003 3.6
Limitation of arm movementd Any 28.5 30.8 0.633 40.7
Mild  26.9 29.3 0.609 38.6
Moderate 2.2 3.8 0.536 2.9
Severe 1.7 4.3 0.147 2.9
Any  local reactione 82.2 75.9 0.052 89.6
Systemic events
Any (≥38 ◦C) 4.0 1.1 0.096 1.5
Mild (≥38 ◦C but <38.5 ◦C) 4.0 1.1 0.096 1.5
Moderate (≥38.5 ◦C but <39 ◦C 0.6 0.0 0.525 0.0
Severe (≥39 ◦C but ≤40 ◦C) 0.0 0.0 >0.99 0.0
>40 ◦C 0.0 0.0 >0.99 0.0
Fatigue 63.2 61.5 0.717 63.3
Headache 54.0 54.4 0.930 65.9
Chills 23.5 24.1 0.919 19.6
Rash  16.5 13.0 0.344 14.2
Vomiting 3.9 5.4 0.546 6.9
Decreased appetite 21.3 21.7 0.937 25.3
New generalized muscle pain 56.2 57.8 0.715 61.8
Aggravated generalized muscle pain 32.6 37.3 0.297 39.9
New generalized joint pain 24.4 30.1 0.195 31.5
Aggravated generalized joint pain 24.9 21.4 0.416 25.6
Any  systemic eventf 82.6 82.1 0.907 84.4
a Exact 2-sided conﬁdence interval and corresponding p-value (based on Chan and Zhang) for the difference in proportions, [13vPnC]–[23vPS], expressed as a percentage.
b Redness and swelling were categorized as absent if <2.5 cm,  mild if ≥2.5 cm and ≤5.0 cm,  moderate if >5.0 cm and ≤10.0 cm, and severe if >10.0 cm.
c If pain at the injection site was present, subjects were asked to enter the severity as mild if the symptom was easily tolerated, moderate if there was discomfort sufﬁcient
to  interfere with usual activity, and severe if the pain was incapacitating.
d If limitation of arm movement was present, subjects were asked to enter the severity as mild if there was some limitation of arm movement, moderate if the subject was
unable to move his or her arm above the head but able to move it above the shoulder, and severe if the subject was unable to move the arm above the shoulder.
e Any local reaction = any pain, any swelling, any redness, or any limitation of arm movement.
f Any systemic event = any fever ≥38 ◦C, any fatigue, any headache, any chills, any rash, any vomiting, any decreased appetite, any new or aggravated generalized muscle
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igher after PCV13 (88.5%) compared to PPSV23 (49.3%) with a
ifference in proportions of 39.2% (95% CI, 33.0%–45.1%).
Because of the higher percentage of females in the PPSV23
roup, an analysis of OPA responses by sex was performed. In these
ex-stratiﬁed analyses of OPA GMTs, the magnitude of the serotype-
peciﬁc effects among females and males was generally similar to
hat among all subjects (data not shown).
A post hoc analysis assessing immune response in subjects with
hronic underlying conditions showed no differences when com-
ared to healthy subjects.
Reverse cumulative distribution curves (RCDCs) showed that
or the 9 serotypes for which PCV13 OPA GMTs were signiﬁcantly
reater than those of PPSV23, the PCV13 curves were generally
igher across the full range of antibody titers (Fig. 2). Serotypes
A and 23F displayed the greatest differences between the PCV13
nd PPSV23 curves.
.2.2. Immune responses to PCV13 at 1 month after vaccination
n subjects 50–59 years of age compared to subjects 60–64 years
f age
OPA GMTs in 50–59 year olds were noninferior to 60–64 year
lds for all 13 serotypes, and statistically signiﬁcantly greater inthe younger cohort for 9 serotypes (Table 2). RCDCs showed that
for the 9 serotypes for which PCV13 OPA GMTs were signiﬁcantly
greater in the 50–59 year old subjects than those in the 60–64 year
old group, the PCV13 curves were generally higher across the full
range of antibody titers (Fig. 2).
3.2.3. Persistence of immune responses at 1 year after vaccination
The immune responses elicited by both vaccines declined
between 1 month and 1 year after vaccination. Nonetheless, the
OPA GMTs remained above the pre-vaccination baseline. The
responses to PCV13 in the 50–59 age group remained consistently
greater than the responses in the older adults (Supplemental Fig.
S1).
3.2.4. Safety
Among subjects 60–64 years of age, the percentage of sub-
jects with severe pain at the injection site was  signiﬁcantly higher
after PPSV23 compared to PCV13 (p = 0.003), and mild pain was
signiﬁcantly higher after PCV13 compared to PPSV23 (p = 0.005)
(Table 3). A higher proportion of 50–59 year old PCV13 recipients
reported pain and limitation of arm movement compared to the
older age group, while the percentages of subjects with swelling
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nd redness were similar in the 2 groups. No notable differences
n systemic events were observed between the PCV13 and PPSV23
roups (Table 3).
The incidence of AEs was similar between PCV13 (17.0%) and
PSV23 (16.7%) recipients and was somewhat lower in the younger
ge cohort (11.4%). Most of the AEs include diseases and conditions
ommonly observed among older adults, and infectious disorders
ere the most frequently occurring types of AEs in all groups. One
1) subject died but the event leading to death was  not considered
elated to the study vaccine, and there were no vaccine related SAEs.
. Discussion
In pneumococcal conjugate vaccines the conjugation of the
apsular polysaccharide to a protein carrier converts the polysac-
haride from a T cell-independent to a T cell-dependent antigen,
ith the potential to elicit more robust and longer-lasting immune
esponses and to establish immune memory. In infants, PCVs are
ighly effective against IPD and also reduce the risk of all-cause
neumonia [6–8]. In older adults PCV7 has been shown to elicit
accine serotype-speciﬁc OPA responses at levels that have been
ssociated with protection in children and that are greater than
hose measured after adult PPSV23 administration [13,16–18].
In addition, PCV7 signiﬁcantly reduced the risk of vaccine-type
PD in a randomized, placebo-controlled trial conducted among
IV-infected adults in Malawi, while a reduction was  not seen in a
tudy of PPSV23 in a similar population of HIV infected adults [8,19].
verall, these observations suggest that PCV immunization may
educe the burden of IPD and potentially non-bacteremic pneumo-
occal pneumonia in adults.
The present study was performed to determine if PCV13, in
omparison to PPSV23, could elicit quantitatively greater anti-
neumococcal functional immune responses, as a result of its T
ell-dependent nature. This is the ﬁrst study comparing safety and
mmunogenicity of PCV13 with PPSV23 in pneumococcal vaccine-
aive older adults 60–64 years of age. The study included adults
ith stable non-immunocompromising chronic diseases which
onetheless increase the risk for pneumococcal disease. Approx-
mately 20% of adults in both age groups had 1 or more of these
onditions. Vaccine serotype-speciﬁc OPA responses to PCV13 were
oninferior to PPSV23 for all 12 serotypes common to both vac-
ines, and were statistically signiﬁcantly higher after PCV13 relative
o PPSV23 for 8 of those serotypes. Similar ﬁndings have been
bserved in other studies for two of the four serotypes (serotypes
 and 14) for which immune responses were not higher in PCV13
ecipients compared to PPSV23 recipients. The biological basis for
his ﬁnding is not known. In addition, PCV13 elicited a statisti-
ally superior response to serotype 6A which is contained only in
CV13. Of note, the functional OPA response against type 6A has
een shown to be cross-reactive with serotype 6C, a serotype that
as recently demonstrated to cause IPD [11,20]. An OPA titer that
orrelates with protection has not been deﬁned; however, RCDCs
howed that for the 9 serotypes for which PCV13 OPA GMTs were
igniﬁcantly greater than those of PPSV23, the PCV13 curves were
enerally higher across the full range of antibody titers.
Responses in 50–59 year olds were noninferior to the older age
roup and statistically signiﬁcantly greater for 9 serotypes, demon-
trating a not unexpected greater response in younger compared
ith older adults. This higher level of response in the younger age
roup notably persisted over the year following vaccination, sug-
esting that vaccination of younger adults may  result in greater
ntibody persistence.
PCV13 had an acceptable safety and reactogenicity proﬁle in
oth the younger and older age groups. In the older age group, mild
ain at the injection site was signiﬁcantly higher after PCV13 and1 (2013) 3577– 3584 3583
severe pain signiﬁcantly higher after PPSV23. Other local reactions
did not differ signiﬁcantly between the two  vaccine groups. There
were no vaccine related AEs or SAEs at the 6 months follow up
contact. Previous studies comparing PCV7 and PPSV23 in vaccine
naive older adults have also found generally comparable safety and
reactogenicity proﬁles [13,17,18].
5. Conclusion
The generally greater functional antibody response to PCV13
compared to PPSV23 in adults conﬁrms the enhanced immuno-
genicity previously seen with T cell-dependent conjugate vaccines,
and supports the perspective that PCV13 has the potential for
improved clinical efﬁcacy against pneumococcal disease. A large,
randomized, placebo-controlled clinical trial to assess the efﬁcacy
of PCV13 against bacteremic and nonbacteremic vaccine type com-
munity acquired pneumonia and IPD is in progress [21].
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